Antibody-Drug-Conjugate (ADC) company reports patient death January 26, 2023 - Magenta Therapeutics’ MGTA-117 blood cancer clinical trial has gone from bad to worse. Weeks after Magenta dropped down a dose level in response to serious adverse events (SAEs), a patient has died after receiving the new, lower dose, prompting the biotech to voluntarily pause the study.
After the latest trial participant was dosed at the cohort 3 level, Magenta said the patient experienced “respiratory failure and cardiac arrest resulting in death” — or what investigators would classify as a Grade 5 serious adverse event.
[Oncy has demonstrated that pelareorep is safe and effective with +1000 patients safely hving the drug administered intravenously]
https://www.fiercebiotech.com/biotech/after-dose-de-escalation-death-drives-magenta-pause-antibody-drug-conjugate-leukemia-trial
[ Gilead acquired ADC company Imuunomedics for US$21 Billion in September 2020 after Immunomedics reported data from a phase 1/2 study in April 2020 that showed the ADC shrank tumors in about 33% of TNBC patients who had received a median of three prior lines of treatment, with the response lasting for a median 7.7 months. It also delayed the time to tumor progression or death for a median 5.5 months and helped these heavily pretreated patients live 13.0 months]
https://www.fiercepharma.com/marketing/turbulent-immunomedics-wins-early-fda-blockbuster-nod-for-adc-triple-negative-breast